Market Closed -
Nyse
21:00:02 10/01/2025 GMT
5-day change
1st Jan Change
26.68 USD
-6.16%
+1.83%
+6.04%
Phreesia Insider Sold Shares Worth $532,560, According to a Recent SEC Filing
December 05, 2024 at 10:50 pm
Phreesia Insider Sold Shares Worth $274,051, According to a Recent SEC Filing
01-08
MT
KeyBanc Raises Price Target on Phreesia to $30 From $28, Keeps Overweight Rating
01-08
MT
RBC Upgrades Phreesia to Outperform From Sector Perform, Raises Price Target to $32 From $24
01-08
MT
Phreesia Insider Sold Shares Worth $536,790, According to a Recent SEC Filing
12-17
MT
Phreesia Insider Sold Shares Worth $294,559, According to a Recent SEC Filing
12-13
MT
Truist Raises Price Target on Phreesia to $34 From $31, Keeps Buy Rating
12-11
MT
Phreesia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2024
12-09
CI
Phreesia, Inc., Q3 2025 Earnings Call, Dec 09, 2024
12-09
Phreesia Fiscal Q3 Loss Narrows, Revenue Rises; FY 2025 Revenue Outlook Narrows; Stock Gains After Hours
12-09
MT
Earnings Flash (PHR) PHREESIA Reports Q3 Revenue $106.8M, vs. Street Est of $106.3M
12-09
MT
Phreesia, Inc. Provides Earnings Guidance for the Fiscal Year 2026
12-09
CI
Phreesia, Inc. Narrows Revenue Guidance for the Fiscal Year 2025
12-09
CI
Phreesia Insider Sold Shares Worth $532,560, According to a Recent SEC Filing
12-05
MT
Phreesia Insider Sold Shares Worth $318,368, According to a Recent SEC Filing
12-04
MT
Phreesia Achieves Oracle Validated Integration with Oracle Health EHR Expertise for Delivering Proven, Repeatable Integration
28/10/24
CI
Phreesia Renews Contract With CMS Innovation Center for Patient Activation Measure Through 2029
01/10/24
MT
Phreesia Secures New Contract with CMS as Report Shows Gains in Patient Activation in First Year of Kidney Care Choices Model
01/10/24
CI
Truist Securities Adjusts Price Target on Phreesia to $31 From $29, Maintains Buy Rating
06/09/24
MT
Phreesia, Inc., Q2 2025 Earnings Call, Sep 04, 2024
04/09/24
Phreesia Fiscal Q2 Loss Narrows, Revenue Rises; Fiscal 2025 Revenue Outlook Reaffirmed
04/09/24
MT
Phreesia Maintains FY 2025 Revenue View of $416-$426 Million, vs CIQ Analyst Consensus of $420 Million
04/09/24
MT
Earnings Flash (PHR) PHREESIA Reports Q2 Revenue $102.1M, vs. Street Est of $101.6M
04/09/24
MT
Earnings Flash (PHR) PHREESIA Reports Q2 Revenue $102.1M, vs. Street Est of $101.6M
04/09/24
MT
Phreesia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2024
04/09/24
CI
Phreesia, Inc. Maintains Revenue Guidance for the Fiscal Year 2025
04/09/24
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
PHR: Dynamic Chart
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. The Company also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
More about the company
Last Close Price
26.68 USD
Average target price
31.50 USD
Spread / Average Target
+18.07%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1